Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 148

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 148
---
 paid by the Company in 2018 and 2019. In a subsequent correspondence, CSL
additionally demanded interest and damages for lost profit, with an aggregate demand amount of $1,476,382.36. The Company has disputed
CSL’s payment demand and contends that CSL’s demands are baseless under the Framework Supply Agreement, as the minimum purchase
commitment under the Framework Supply Agreement is conditional upon first obtaining approval of the FDA and the European Medicines Evaluation
Agency, or EMEA, and other quality and clinical milestones, none of which has occurred. Notwithstanding, CSL claimed to have obtained
a valid German court order in its favor and to endeavor to seek for its enforcement in Israel. Our position is that CSL’s claim
for the payment of the said unshipped minimum purchase commitments lacks any ground under the terms of the Framework Supply Agreement
and moreover, that we were never served with German judicial documents (e.g., statement of claim) of CSL with translations in Hebrew,
English or Arabic, as required under the applicable German and international rules of proceeding. Consequently, based on advice of a
German legal counsel, we are in the opinion that the legal proceeding initiated by CSL suffered a fundamental and material procedural
error and that no enforceable German judgement could derive thereto. In 2024, we have initiated a proceeding in Germany to annul said
German court’s purported ruling.

Other than the proceeding
mentioned above, we are not currently a party to any material legal proceedings. We may, however, in the ordinary course of business
face various claims brought by third parties and we may, from time to time, make claims or take legal actions to assert our rights, including
intellectual property rights as well as claims relating to employment matters and the safety or efficacy of our products. Any of these
claims could subject us to costly litigation and, while we generally believe that we have adequate insurance to cover many different
types of liabilities, our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid claims, or our policy
limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could
have a material adverse effect on our operations, cash flows and financial position. Additionally, any such claims, whether or not successful,
could damage our reputation and business.

<div align='center'>89

MANAGEMENT</div>

Executive Officers and Directors

The following table sets
forth information regarding our executive officers and